Wishart J M
N Z Med J. 1984 Feb 22;97(750):115-7.
Twenty-eight patients with severe acne and one with hidradenitis suppurativa and acne were treated for 12 to 16 weeks with a new synthetic retinoid, isotretinoin (Roaccutane). The average dose was 0.56 mg/kg/day. Patients were seen weekly for four weeks and then fortnightly for the remaining treatment period, being evaluated both qualitatively and quantitatively. Twenty-five patients had an excellent response. Two to five months after the end of treatment no patient had relapsed. No patient withdrew because of side effects, but all suffered dry lips. This study confirms the potential of isotretinoin in the treatment of severe acne.
28名重度痤疮患者和1名化脓性汗腺炎合并痤疮患者接受了一种新型合成维甲酸异维A酸(Roaccutane)治疗,疗程为12至16周。平均剂量为0.56毫克/千克/天。患者在最初四周每周就诊,之后在剩余治疗期间每两周就诊一次,接受定性和定量评估。25名患者反应极佳。治疗结束后两到五个月,无患者复发。没有患者因副作用退出治疗,但所有患者均出现嘴唇干燥。本研究证实了异维A酸治疗重度痤疮的潜力。